Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · IEX Real-Time Price · USD
9.20
+0.08 (0.88%)
At close: May 17, 2024, 4:00 PM
9.12
-0.08 (-0.87%)
After-hours: May 17, 2024, 7:57 PM EDT
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for ARQT stock have an average target of 28.14, with a low estimate of 10 and a high estimate of 50. The average target predicts an increase of 205.87% from the current stock price of 9.20.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ARQT stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
Buy | 4 | 4 | 4 | 4 | 3 | 3 |
Hold | 3 | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 9 | 9 | 9 | 9 | 8 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Needham | Needham | Strong Buy Maintains $16 → $18 | Strong Buy | Maintains | $16 → $18 | +95.65% | May 15, 2024 |
Mizuho | Mizuho | Strong Buy Maintains $17 → $18 | Strong Buy | Maintains | $17 → $18 | +95.65% | May 15, 2024 |
Needham | Needham | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +73.91% | Apr 12, 2024 |
Goldman Sachs | Goldman Sachs | Hold Maintains $6 → $11 | Hold | Maintains | $6 → $11 | +19.57% | Feb 28, 2024 |
Mizuho | Mizuho | Strong Buy Reiterates $16 → $17 | Strong Buy | Reiterates | $16 → $17 | +84.78% | Feb 28, 2024 |
Financial Forecast
Revenue This Year
107.38M
from 59.61M
Increased by 80.15%
Revenue Next Year
218.24M
from 107.38M
Increased by 103.24%
EPS This Year
-2.56
from -3.78
EPS Next Year
-1.49
from -2.56
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 128.6M | 261.5M | 454.6M | 741.3M | 1,000.0M |
Avg | 107.4M | 218.2M | 369.6M | 589.1M | 747.4M |
Low | 73.5M | 161.7M | 310.5M | 507.0M | 628.1M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 115.8% | 143.5% | 108.3% | 100.6% | 69.8% |
Avg | 80.1% | 103.2% | 69.4% | 59.4% | 26.9% |
Low | 23.3% | 50.6% | 42.3% | 37.2% | 6.6% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -2.32 | -1.12 | 0.30 | 2.75 | 4.79 |
Avg | -2.56 | -1.49 | -0.33 | 1.31 | 2.35 |
Low | -3.08 | -1.91 | -0.74 | 0.59 | 1.00 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 265.6% |
Avg | - | - | - | - | 79.1% |
Low | - | - | - | - | -23.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.